37 results on '"Cahn, Avivit"'
Search Results
2. Gestational diabetes and risk of future diabetes in a multi-ethnic population
3. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
4. SGLT2 Inhibitors and Safety in Older Patients
5. Diagnosis and Risk Factors of Prediabetes and Diabetes in People Living With Human Immunodeficiency Virus: Evaluation of Clinical and Microbiome Parameters.
6. Predictors and outcomes of diabetic foot ulcer infection with ESBL-producing bacteria in a large tertiary center
7. Reported iodinated contrast media allergy is a risk factor for anaphylaxis-independent mortality in hospitalized patients
8. Abstract 14726: Serial Assessment of Cardiac Biomarkers and Risk of Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58
9. Abstract 10006: The Effect of Dapagliflozin on Hospital Admissions in Patients With Type 2 Diabetes: Post Hoc Analysis of the DECLARE-TIMI 58 Trial
10. Complex rearrangement in TBC1D4 in an individual with diabetes due to severe insulin resistance syndrome
11. Cardio‐renal‐metabolic disease in primary care setting.
12. Prescription patterns in people who are frail
13. Alpelisib in Intractable Non–Islet-Cell Tumor Hypoglycemia
14. Enterococci in diabetic foot infections: Prevalence, Clinical Characteristics, and Outcomes
15. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes
16. Complex rearrangement in TBC1D4in an individual with diabetes due to severe insulin resistance syndrome
17. RELATIONSHIP BETWEEN CYSTATIN C, CREATININE-BASED EGFR, CARDIOVASCULAR EVENTS AND KIDNEY OUTCOMES IN DECLARETIMI 58
18. Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58
19. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes A Secondary Analysis of the DECLARE-TIMI 58 Trial
20. Acute diabetic foot in post kidney transplantation patients receiving chronic immunosuppression—clinical presentation and outcomes
21. Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes
22. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes– post hoc analyses from the DECLARE-TIMI 58 trial
23. Consistency of Thyroid Imaging Reporting and Data System Reporting in Community-Based Imaging Centers Versus a Large Tertiary Hospital
24. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial
25. FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58
26. Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
27. Abstract 13182: Dapagliflozin and Changes in Metabolic Syndrome in Patients With Type 2 Diabetes: A DECLARE TIMI 58 Sub-Analysis
28. Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58.
29. Angiogenic potential of mesenchymal stem cells derived from patients with diabetes seeded on decellularized micro fragments
30. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.
31. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial.
32. Machine learning based study of longitudinal HbA1c trends and their association with all‐cause mortality: Analyses from a National Diabetes Registry.
33. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes.
34. Oxycodone-Acetaminophen Abuse by Inhalation.
35. Diagnosis and Risk Factors of Prediabetes and Diabetes in People Living With Human Immunodeficiency Virus: Evaluation of Clinical and Microbiome Parameters.
36. [HOSPITALIZATIONS DUE TO ACUTE DIABETIC FOOT: ANNUAL TRENDS AND PREDICTORS OF MORBIDITY AND MORTALITY - 5-YEARS EXPERIENCE OF A MULTIDISCIPLINARY UNIT].
37. [DIABETIC FOOT IN ISRAEL - CURRENT STATUS AND FUTURE PERSPECTIVES].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.